Description of the medicine: Midantanum

Midantanum. 1-Aminoadamantane hydrochloride, or 1-adamantanamine hydrochloride.

Synonyms: Viregit, Adamantin, Amandin, Amantadine hydrochloridum, Amantadine hydrochoride, Amantan, Antadine, Atarin, Fluviatol, Gabirol, Mantadix, Mydantan, Paramentin, Protexin, Symmetrel, Viregit, Virofral, Virosol and others.

White crystalline powder of bitter taste. Soluble in water, easily - in alcohol.

The drug was originally proposed as an antiviral agent effective against influenza viruses type A2. Subsequently, its effectiveness was revealed in parkinsonism.

The mechanism of the therapeutic effect of midantane in Parkinsonism is explained by the fact that it stimulates the release of dopamine from neuronal depots and increases the sensitivity of dopaminergic receptors to the mediator (dopamine); Thus, even with a decrease in the formation of dopamine in the basal ganglia, conditions are created to normalize the neurophysiological processes that take place in them. There is also evidence that midtanan inhibits the generation of impulses in the motor neurons of the central nervous system.

Apply midantan with Parkinson's disease and parksinsonizme different etiology. The drug is effective mainly in rigid and akinetic forms, less affects hyperkinetic syndrome (tremor).

Information on the effectiveness of midantan as a corrector of neuroleptic syndrome is contradictory. According to some authors, the drug can be used for this purpose, according to others, its use is inexpedient, since it is ineffective in medium doses, and in large doses it can cause an exacerbation of psychopathological symptoms.

Midantan is a high-speed drug, the effect usually occurs in the first days of treatment.

The drug can be administered alone and in combination with other antiparkinsonian drugs: anticholinergics and L-dopa.

Assign midantan inside after eating. Accept, starting with 0.05 - 0.1 g, first 2 times, then 3 - 4 times a day. Daily doses of 0.2 - 0.4 g. Duration of treatment 2 - 4 months.

The drug is usually well tolerated. In some cases, there may be headache, insomnia, dizziness, general weakness, dyspepsia. If necessary, reduce the dose.

Milantan is contraindicated in acute and chronic diseases of the liver and kidneys, as well as in the case of a 6-change. In connection with the possible initiation of the CNS, the drug should be administered with caution to patients with mental illnesses, with thyrotoxicosis, epilepsy.

Product: tablets of 0.1 g, coated with a yellow color, in a package of 100 pieces.

Storage: List B. In a dry place.

Rr .: Tab. Midantani 0.1 obd. N. 100

DS